Development and preliminary evaluation of the Conventional Medicine Disclosure Index.

Communication barriers Complementary medicine Disclosure Instrument development Patient communication Pharmaceutical dugs

Journal

Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974

Informations de publication

Date de publication:
10 2021
Historique:
received: 24 04 2020
revised: 26 01 2021
accepted: 26 01 2021
pubmed: 10 2 2021
medline: 22 9 2021
entrez: 9 2 2021
Statut: ppublish

Résumé

Non-disclosure of conventional medicine use to complementary medicine health professionals may result in patient harm. Currently, no standardised validated instrument is available to measure reasons for conventional medicine disclosure or non-disclosure. The aim of this study was to develop and evaluate a multidimensional index for identifying reasons for conventional medicine disclosure and non-disclosure by patients. Drawing upon a sub-sample of the Complementary and Alternative Medicine Use Health Literacy Disclosure Study (N = 520), a formative measurement approach was used to develop a Conventional Medicine Disclosure Index (CONMED-DI). Variance-based structural equation modelling employing partial least squares evaluated multicollinearity, significance and relevance of the formative indicators to their associated primary constructs. The CONMED-DI demonstrated adequate construct validity suggesting the CONMED-DI is a pragmatic measure to determine the reasons why people choose to disclose (or not) their conventional medicine use. The CONMED-DI contains 2 second-order measurement models, both with three sub-domains. The CONMED-DI serves as a preliminary instrument primarily of value to researchers interested in exploring the complementary medicine clinical encounter. The development of targeted interventions that promote disclosure of conventional medicine can be facilitated through understanding patients' reasons for disclosure and non-disclosure and optimise patients' safe use of medicines.

Sections du résumé

BACKGROUND
Non-disclosure of conventional medicine use to complementary medicine health professionals may result in patient harm. Currently, no standardised validated instrument is available to measure reasons for conventional medicine disclosure or non-disclosure.
OBJECTIVE
The aim of this study was to develop and evaluate a multidimensional index for identifying reasons for conventional medicine disclosure and non-disclosure by patients.
METHODS
Drawing upon a sub-sample of the Complementary and Alternative Medicine Use Health Literacy Disclosure Study (N = 520), a formative measurement approach was used to develop a Conventional Medicine Disclosure Index (CONMED-DI). Variance-based structural equation modelling employing partial least squares evaluated multicollinearity, significance and relevance of the formative indicators to their associated primary constructs.
RESULTS
The CONMED-DI demonstrated adequate construct validity suggesting the CONMED-DI is a pragmatic measure to determine the reasons why people choose to disclose (or not) their conventional medicine use. The CONMED-DI contains 2 second-order measurement models, both with three sub-domains.
CONCLUSION
The CONMED-DI serves as a preliminary instrument primarily of value to researchers interested in exploring the complementary medicine clinical encounter. The development of targeted interventions that promote disclosure of conventional medicine can be facilitated through understanding patients' reasons for disclosure and non-disclosure and optimise patients' safe use of medicines.

Identifiants

pubmed: 33558156
pii: S1551-7411(21)00038-3
doi: 10.1016/j.sapharm.2021.01.015
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1791-1799

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Erica McIntyre (E)

School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia; Institute for Sustainable Futures, University of Technology Sydney, Ultimo, Australia. Electronic address: erica.mcintyre@uts.edu.au.

Hope Foley (H)

School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia. Electronic address: hope.m.foley@student.uts.edu.au.

Joanna Harnett (J)

School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia; The University of Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Electronic address: joanna.harnett@sydney.edu.au.

Jon Adams (J)

School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia. Electronic address: jon.adams@uts.edu.au.

Amie Steel (A)

School of Public Health, Faculty of Health, University of Technology Sydney, Ultimo, Australia. Electronic address: amie.steel@uts.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH